Brief communication

Breast Cancer Research and Treatment

, Volume 89, Issue 2, pp 209-212

First online:

Inhibition of metastasis by inhibition of tumor-derived CCL5

  • Kerry A. StormesAffiliated withDepartment of Biology, Lafayette College
  • , Charles A. LemkenAffiliated withDepartment of Biology, Lafayette College
  • , James V. LepreAffiliated withDepartment of Biology, Lafayette College
  • , Michelle N. MarinucciAffiliated withDepartment of Biology, Lafayette College
  • , Robert A. KurtAffiliated withDepartment of Biology, Lafayette College Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


To determine whether tumor-derived CCL5 contributes to the metastatic potential of murine mammary carcinoma, we used the 4T1 tumor which spontaneously metastasizes and constitutively produces CCL5. Mice bearing 4T1 that expressed less CCL5 had significantly fewer lung and liver metastasis. The decrease in tumor-derived CCL5 also correlated with decreased cathepsin L, MMP-2, MMP-3, MMP-10 and MMP-17 gene expression. Thus, inhibition of tumor-derived CCL5 can impact the metastatic capability of 4T1 and may do so by modulating protease expression.

Key words

breast cancer CCL5 metastasis RANTES 4T1